Ensysce Biosciences Inc. Demonstrates Carbon Nanotube Delivery of RNA to PBMCs
08 July 2015 - 8:54AM
Business Wire
Ensysce Biosciences Inc. efforts in the development of the
single walled carbon nanotube (SWCNT) delivery platform for
therapeutic applications has led to the important finding that
SWCNT can transfect peripheral blood mononuclear cells (PBMCs)
following intravenous administration. Ensysce has data
demonstrating that SWCNT form stable complexes with oligonucleotide
payloads, including full length RNA and plasmid DNA. These SWCNT
complexes facilitate the delivery of large biologically active
agents through natural barriers within the body, and readily into
PBMC. Ensysce has also shown the complexes can be formulated to
control relative tissue distribution following intravenous
administration.
Oligonucleotide delivery especially to PBMCs has been a focus of
intense research for years and as seen with the CART therapy is
currently limited to in vitro methods using viral vectors or
mechanical electroporation. The ability of SWCNT to enable in vivo
transfection of PBMCs would be a significant accomplishment for
this field which may lead to novel therapeutic approaches for the
CART and crisper technologies.
About Ensysce Biosciences:
Ensysce has an extensive carbon nanotube-related, worldwide
intellectual property portfolio, including IP developed at Rice
University by the late Nobel Prize winner Dr Richard Smalley as
well as from the University of Florida and Trinity College in
Dublin. Ensysce was recently issued a US patent to extend its
intellectual property coverage for the use of SWCNT for therapeutic
applications.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150707006608/en/
Ensysce Biosciences Inc.Dr. D. Lynn Kirkpatrick,
858-242-1539